75
Participants
Start Date
May 31, 2005
Primary Completion Date
January 31, 2007
Study Completion Date
January 31, 2007
AMA1-C1/Alhydrogel®
AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection
CPG 7909 Oligodeoxynucleotide (VaxImmune®)
CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.
University of Rochester, Rochester
National Institute of Allergy and Infectious Diseases (NIAID)
NIH